First COVID-19 Patient Treated with Inhaled Nitric Oxide Therapy; Prior Studies Have Shown NO May Prevent Viral Replication, Improve Arterial Oxygenation, Reduce Need for Ventilation Support, & Prevent Proliferation of Lung Infiltrates

On March 30, 2020, Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that emergency expanded access treatment with its INOpulse(R) inhaled nitric oxide (iNO) system (iNO) was initiated for the first time in a patient with a diagnosis of the novel coronavirus disease COVID-19 at the University of Miami School of Medicine. The treatment follows the recent decision by the U.S. Food and Drug Administration (FDA) to grant emergency expanded access that allows INOpulse to be used immediately for the treatment of COVID-19 under the care and supervision of the patient’s physician. "Based on previous studies that demonstrate the benefits of iNO in oxygenation and immune response, INOpulse has the potential to be used as a viable treatment option for COVID-19," said the treating physician, Roger Alvarez, DO, MPH, Assistant Professor, University of Miami School of Medicine. "The cardiopulmonary benefit demonstrated by INOpulse in various indications provides the potential to prevent deterioration in patients with COVID-19, allowing ventilators to be preserved for the most critically ill. INOpulse's ease of administration could significantly decrease the burden on therapists and nurses as they combat this pandemic with constrained resources." NO is a molecule naturally produced in the endothelial lining of blood vessels that plays a significant role in vasodilation, or opening of the arteries, including arteries in the lung.
Login Or Register To Read Full Story